Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression

Genomically amplified fibroblast growth factor receptor 1 (FGFR1) is an oncogenic driver in defined lung cancer subgroups and predicts sensibility against FGFR1 inhibitors in this patient cohort. The FGFR inhibitor nintedanib has recently been approved for treatment of lung adenocarcinoma and is cur...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Englinger, Bernhard, Lötsch, Daniela, Pirker, Christine, Mohr, Thomas, van Schoonhoven, Sushilla, Boidol, Bernd, Lardeau, Charles-Hugues, Spitzwieser, Melanie, Szabó, Pál, Heffeter, Petra, Lang, Irene, Cichna-Markl, Margit, Grasl-Kraupp, Bettina, Marian, Brigitte, Grusch, Michael, Kubicek, Stefan, Szakács, Gergely, Berger, Walter
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2016
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5226575/
https://ncbi.nlm.nih.gov/pubmed/27367030
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10324
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller